Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.44 USD
-0.01 (-0.29%)
Updated Sep 25, 2024 03:40 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 1 - 20 ( 448 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- Going for the Gold Medal: Cell Therapy in Autoimmune Disease
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Allo, Bringing New Potluck Dishes to the II CART
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways for ASCO 2024; Roundup for Covered Companies (Pt. 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gene Juice: ASGCT Recap - Large Gene Insertion; Epigenetic Editing & More
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M